Yongqi Xiao, PharmD Candidate, 2025, Chi Ying Chan, PharmD Candidate, 2025, Ali Zalpour, PharmD, BCPS, MD Anderson Cancer Center, Haley Tierce, PharmD, BCPS, MD Anderson Cancer Center
Published: September 18, 2024
Intravenous β-lactam (BL) agents are the primary treatments for gram-negative bloodstream infections (GN-BSI), which are commonly caused by pathogens such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella spp.1 These agents exhibit a time-dependent effect on bacterial eradication, with optimal bactericidal effect achieved when the drug serum concentration exceeds ...
Dawn Havrda, PharmD, BCPS, FCCP
Published: September 18, 2024
The coexistence of atrial fibrillation (AF) with coronary artery disease (CAD) occurs in about 40% of patients and is more common with increasing age. AF increases the risk of cardioembolic stroke; therefore, chronic oral anticoagulation is recommended to prevent stroke and is superior to antiplatelet therapy. A common management strategy ...
Dawn Havrda, PharmD, BCPS, FCCP
Published: June 3, 2024
Coronary heart disease is common affecting 4.9% of adults and is the leading cause of death.1 Persons can present with acute coronary syndromes (ACSs), which include unstable angina, non–ST-elevation myocardial infarction (NSTEMI), or ST-elevation myocardial infarction (STEMI).2 Much evidence is available to guide therapy in ACS and a ...